AtriCure (NASDAQ:ATRC) Issues FY 2026 Earnings Guidance

AtriCure (NASDAQ:ATRC) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 0.000-0.040 for the period, compared to the consensus EPS estimate of 0.130. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $604.1 million.

AtriCure Price Performance

NASDAQ:ATRC traded up $0.21 during trading hours on Thursday, reaching $28.22. 212,034 shares of the company’s stock were exchanged, compared to its average volume of 703,320. The company has a market capitalization of $1.43 billion, a P/E ratio of -282.45 and a beta of 1.28. AtriCure has a 12 month low of $26.62 and a 12 month high of $43.18. The company has a quick ratio of 2.99, a current ratio of 3.96 and a debt-to-equity ratio of 0.13. The business’s 50-day simple moving average is $29.30 and its two-hundred day simple moving average is $34.35.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Tuesday, May 5th. The medical device company reported $0.00 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.07. The firm had revenue of $141.25 million for the quarter, compared to analysts’ expectations of $139.75 million. AtriCure had a negative net margin of 0.83% and a positive return on equity of 0.29%. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.14) EPS. AtriCure has set its FY 2026 guidance at 0.000-0.040 EPS. Sell-side analysts expect that AtriCure will post 0.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ATRC shares. Citigroup reiterated an “outperform” rating on shares of AtriCure in a research report on Wednesday, February 18th. Needham & Company LLC restated a “buy” rating and issued a $45.00 price target on shares of AtriCure in a research report on Thursday, February 12th. Oppenheimer lowered shares of AtriCure from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 18th. UBS Group reduced their price target on shares of AtriCure from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, February 18th. Finally, Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $48.71.

Insider Buying and Selling

In other AtriCure news, insider Vinayak Doraiswamy sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $29.83, for a total value of $149,150.00. Following the completion of the sale, the insider owned 96,875 shares of the company’s stock, valued at approximately $2,889,781.25. This represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On AtriCure

A number of hedge funds have recently bought and sold shares of ATRC. Wellington Management Group LLP grew its stake in AtriCure by 8.1% during the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock worth $151,296,000 after buying an additional 322,818 shares in the last quarter. First Light Asset Management LLC boosted its position in AtriCure by 32.0% during the 4th quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after buying an additional 285,083 shares during the period. Dimensional Fund Advisors LP boosted its position in AtriCure by 8.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 921,897 shares of the medical device company’s stock worth $36,472,000 after buying an additional 71,341 shares during the period. Marshall Wace LLP boosted its position in AtriCure by 63.4% during the 4th quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company’s stock worth $36,136,000 after buying an additional 354,281 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in AtriCure by 13.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 885,062 shares of the medical device company’s stock worth $35,013,000 after buying an additional 107,754 shares during the period. 99.11% of the stock is owned by institutional investors.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.